Feed BTAI
BT
BioXcel Therapeutics, Inc. BTAI · NASDAQ
$0.07 -18.79% (-$0.02)
Summary
44 / 100 · Bulios Score
Valuation 57Growth 100Profitability 18Quality 58Debt 0Stability 19
What speaks for it
- Revenue grew by 20% a year over the last 3 years.
- It earns 1,145 USD a year on every 100 USD of invested capital.
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 20% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $70.9M.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $12.8M
Debt $104.5M
Free cash flow over 12 months -$50.9M
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 6
- Sell 1
No analyst has published a price target.
53% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.